Small Molecule Drug Discovery Market Forecasts to 2028 – Global Analysis By Therapeutic Area(Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal and Other Therapeutic Areas), Process/Phase (Target ID/Valida

Small Molecule Drug Discovery Market Forecasts to 2028 – Global Analysis By Therapeutic Area(Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal and Other Therapeutic Areas), Process/Phase (Target ID/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization), End User (Pharmaceutical & biotechnology companies and Academic Institutes) and By GeographyAccording to Stratistics MRC, the Global Small Molecule Drug Discovery Market is accounted for $ 34621.82 million 2022 and is expected to reach $ 66527.18 million by 2028 growing at a CAGR of 11.5% during the forecast period Small molecular drugs, which penetrate through the cell membrane and act on a particular cellular organelle or protein, are employed in targeted drug delivery. Due to their low molecular weight, tiny molecules medications can easily enter cells. Due to their size, simplicity in converting to an oral form, and cost-effectiveness, these molecules perform better than monoclonal antibodies and other large molecular medications.

According to the Centres for Disease Control (CDC), 6 in 10 adults suffer from a chronic condition, such as heart disease, diabetes, cancer, kidney disease, lung disease, or stroke in the US, costing US$ 3.5 trillion to the economy in the US annually for the treatment of these chronic diseases. Chronic diseases are the most significant cause of deaths worldwide, and the number is growing every year.

Market Dynamics:

Driver:

Increasing number of chronic diseases

The rise of chronic illnesses fuels the market's expansion. According to data from the British Heart Foundation from August 2022, 7.6 million persons in the UK were affected by heart or cardiovascular disease in 2021. Globally, there were 19.3 million new cases of cancer in 2020, and this figure is projected to rise to 30.2 million by 2040, according to GLOBOCAN 2020 estimates. It is anticipated that the prevalence of chronic diseases will raise treatment demand, which will ultimately boost small molecule demand. Consequently, it is anticipated to fuel the market's expansion.

Restraint:

High drug development costs and strict regulations

Over the forecast period, the market's expansion is anticipated to be constrained by high drug development costs and strict regulations for drug development.

Opportunity:

Rising technological advancements

Rising technical breakthroughs and a preference for small molecules, combined with increasing illness complications, have prompted leading players to raise their R&D expenditure, which is also functioning as a major growth factor for the market.

Threat:

Complex and costly process

Small molecule drug development is a time-consuming, difficult, and expensive process that is rife with doubt about whether a certain drug will be successful.

Covid-19 Impact

The health systems of nations have been making significant investments in R&D to tackle the COVID-19 virus. Research teams from all across the world are working to find small molecule medications for COVID-19 by testing both brand-new and off-the-shelf medications for their capacity to reduce symptoms and stop viral replication. In light of the ongoing pandemic, the need to identify a treatment for COVID-19 is thus anticipated to have a beneficial impact on the small molecule drug discovery industry.

The oncology segment is expected to be the largest during the forecast period

Based on the therapeutic area, the market is classified into Oncology, Central Nervous System, Cardiovascular, Respiratory, Metabolic Disorders, Gastrointestinal and Other Therapeutic Areas. The oncology segment is projected to control the global small molecule drug discovery market and most liable explanation for the majority of the share during the forecast period. Due to the rising number of small molecule medication approvals and expanding pipeline for cancer therapies, the oncology category maintained the biggest market share in 2019. Additionally, the segment's growth is being further driving by rising oncology investment.

The target id/validation segment is expected to have the highest CAGR during the forecast period

Based on the process/phase, the market is segmented into Target ID/Validation, Hit Generation and Selection, Lead Identification and Lead Optimization. The target id/validation segment is captured to be more profitable and predicted to record a strong CAGR during the forecast period. A tiny molecule's direct molecular target, such as a protein or nucleic acid, is identified through the process of target identification. Target identification in clinical pharmacology is to determine the effectiveness of the medication molecule's target. The fundamental goal of target validation is to determine and assess a molecular target's potential for aiding in the production of medicines with therapeutic applications.

Region with highest share:

North America is anticipated to hold the highest share during the forecast period. Owing to the rising rates of different chronic diseases, including cancer, cardiovascular disease, and others, as well as the increasing acceptance of new small molecules in the area, are the main reasons propelling the market's expansion. The FDA reports that the Center for Drug Evaluation and Research (CDER) approved 48 new medications in 2019.

Region with highest CAGR:

North America small molecule drug discovery market is one of the fastest-growing regions and also records highest CAGR during the forecast period. This is due the Pharmaceutical Research and Manufacturers of America (PhRMA) member businesses continue to be at the forefront of the discovery of new medications, and the American pharmaceutical sector has long been one of the global leaders in this field. Six grants were given out by the Food and Drug Administration in 2020 to fund new clinical trials and advance the creation of pharmaceuticals for the treatment of uncommon diseases. Due to their widespread use in the drug discovery process, this will increase the demand for small molecule drug discovery.

Key players in the market

Some of the key players profiled in the Small Molecule Drug Discovery Market include 21st Century Therapeutics Inc., Gilead Sciences Inc., BioNTech (4SC-Discovery ), Bristol-Myers Squibb Company, Acacia Pharma Gr, AstraZeneca, Agilent Technologies Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Takeda Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc., Merck KGaA, Novartis, Teva Pharmaceuticals Inc.

Key Developments:

In August 2022, BioDuro-Sundia and X-Chem, a DEL technology pioneer in small molecule drug discovery, launched DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs.

In July 2022, RxCelerate launched RxNfinit. It is a new small molecule discovery platform that leverages machine learning, in silico structure modeling, and combinatorial chemistry in a novel workflow to offer significant advantages over the current generation of tools to identify small molecule drugs against a wide range of protein targets.

Therapeutic Area Covered:
• Oncology
• Central Nervous System
• Cardiovascular
• Respiratory
• Metabolic Disorders
• Gastrointestinal
• Other Therapeutic Areas

Process/Phase Covered:
• Target ID/Validation
• Hit Generation and Selection
• Lead Identification
• Lead Optimizations

End User Covered:
• Pharmaceutical & biotechnology companies
• Academic Institutes

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
Comprehensive profiling of additional market players (up to 3)
SWOT Analysis of key players (up to 3)
• Regional Segmentation
Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances